Regeneron Surges to 139th in Market Rankings with $572 Million Trading Volume

On April 22, 2025, Regeneron's trading volume reached $572 million, marking a significant increase of 36.67% compared to the previous day. This surge placed Regeneron at the 139th position in the day's stock market rankings. The company's stock price also rose by 4.27%.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that its board of directors has declared a quarterly dividend of $1.15 per share on the company's common stock. The dividend is payable on June 14, 2025, to stockholders of record at the close of business on May 31, 2025. This dividend declaration reflects the company's strong financial performance and commitment to returning value to its shareholders.

Regeneron has also reported positive results from its Phase 3 clinical trial for a new drug candidate aimed at treating a rare genetic disorder. The trial met its primary endpoint, demonstrating a statistically significant improvement in patients' symptoms compared to the placebo group. This success is expected to accelerate the drug's regulatory approval process and expand Regeneron's portfolio of innovative therapies.

Additionally, Regeneron has entered into a strategic collaboration with a leading biotechnology company to develop and commercialize a novel immunotherapy for cancer treatment. The collaboration will leverage Regeneron's expertise in antibody discovery and the partner's advanced cell therapy platform, aiming to bring a groundbreaking treatment to patients with limited therapeutic options.